* Program subject to change
Kwang Hyub Han, MD, PhD
National Evidence-based Healthcare Collaborating Agency, Seoul, Korea, Republic of (South)
Shawn Vasoo, MBBS, MRCP, D (ABIM) (Infectious Diseases)
National Centre for Infectious Diseases, Tan Tock Seng Hospital, -, Singapore
Wang-jun Lee, MD, PhD
Myongii Hospital, Seoul, Korea, Republic of (South)
Kenji Shibuya, MD, DrPH
King’s College, London, United Kingdom
Fan Wu, MD, PhD
Shanghai Medical College of Fudan University, Shanghai, China
Live
Day 1 Topic: COVID-19 in Asia Pacific: A discussion on the way forward
Moderators: Robert Selby and Clarissa Cooblall, ISPOR
Panelists: Isao Kamae, DrPH, MD, University of Tokyo, Japan; Paul Scuffham, PhD, Griffith University, Australia; Hwee Lin Wee, PhD, National University of Singapore; Richard J. Willke, PhD, ISPOR; Lucinda Orsini, DPM, MPH, ISPOR
This 30-minute session brings together an esteemed panel of thought leaders in the region to talk about how COVID-19 is impacting the Asia Pacific and HEOR’s role in this new environment. How must healthcare and decision-making adapt in the new post-COVID landscape? What is the future of HEOR in the post-COVID era? These are just some of the questions we will be debating. Join us for this interactive session.
ISSUE
OVERVIEW
John Lim, MD, MSc, SM
Centre of Regulatory Excellence, Duke-NUS Medical School, Singapore; Consortium for Clinical Research & Innovation Singapore, Singapore, 01, Singapore
Churn-Shiouh Gau, Ph.D
National Taiwan University, Taipei, TPQ, Taiwan
Jin Hyoung Kang, M.D. Ph.D
Seoul St. Mary’s Hospital The Catholic University of Korea, Seoul, Korea, Republic of (South)
Jipan Xie, MD, PhD
Analysis Group, Inc., Los Angeles, CA, USA
Wonjoo Jung, MSc
Johnson & Johnson, Singapore, 01, Singapore
Woo Jin Hyung, MD, PhD
Severance Hospital, Yonsei University Health System, Seoul, South Korea
Joo Youn Kim, DVM, PhD
Jae Yoo, MBA
Korea Medical Devices Industry Association, Seoul, 41, South Korea
ISSUE: Leading experts and key stakeholders in the health economics and outcomes research community in European countries and North America have discussed value assessment frameworks beyond QALY metric. However, they were rarely considered or discussed among countries in Asia. Panelists will discuss their views on various value assessment frameworks and how these frameworks fit with the healthcare decision context in Asian countries from academic, payer, and industry perspectives.
Nathorn Chaiyakunapruk, PharmD, PhD
University of Utah, Salt Lake City, UT, USA
Eun-Young Bae, PhD
Gyong-Sang National University, South Korea, Jinju, Gyeongnam province, 48, South Korea
Christoph Glaetzer, Dipl. Kfm
Janssen, Pharmaceutical Companies of Johnson&Johnson, Raritan, NJ, USA
Surachat Ngorsuraches, PhD
Auburn University, Harrison School of Pharmacy, Auburn, AL, USA
Panel experts from Asia and the US will highlight opportunities and challenges of SAT in personalized medicine and share their experience and raise considerations of new methodology. The objective of this panel is to continue exploring a better framework how SAT should be considered from access perspective for the ultimate goal of improving patient care to innovative medical technology.
Amgen Inc.
Delphine Courmier, PhD, MBA
AMGEN, Thousand Oaks, CA, USA
Bor-Sheng Ko, M.D. Ph.D.
National Taiwan University Hospital, New Taipei City, TPE, Taiwan
Jeremy Rassen, ScD
Aetion, Inc., New York, NY, USA
Jing Wu, PhD
Tianjin University, Tianjin, China
Jeonghoon Ahn, PhD
Ewha Womans University, Seoul, Korea, Republic of (South)
Takashi Fukuda, PhD
Deallus Consulting, Tokyo, Japan
Yoko Ishiguro, Masters in Public Policy
Medtronic, Tokyo, Japan
Chaemin Shin, PhD
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, 41, South Korea
ISSUE: Several limitations and challenges have been identified when conducting economic evaluations of gene replacement therapies (GRT) using standard approaches, such as recommended by HTA organisations using cost-effectiveness analysis as a key driver of decisions. These include in particular: 1) assessment of clinical effectiveness and safety based on small clinical trials, often single-arm; 2) valuation of health outcomes for children, who are often targeted by GRT; 3) time horizon and extrapolation, as there is substantial uncertainty long-term effects, positive or negative; 4) possible development of new payment models specific to GRT. The panel will provide a forum to discuss potential solutions for key methodological issues in health economic evaluation of gene replacement therapies.
OVERVIEW: The moderator will initiate the debate by providing an overview of the gene replacement therapies pipeline and the evidence in development. He will introduce four questions on which the panellists will debate. 1) Under which conditions are single-arm studies acceptable and sufficient for decision-making? 2) Should generic utility instruments like EQ-5D be used for the valuation of health outcomes in severe paediatric diseases? 3) Are analyses over a lifetime horizon feasible and appropriate despite substantial uncertainty around the long-term efficacy and safety? Extrapolation approaches will be discussed. 4) Are the difficulties of economic evaluations for GRT alleviated with the use of new payment models? The panellists, Mondher Toumi, Ataru Igarashi, and Omar Dabbous, will succinctly present their position on these questions, providing academic and industry perspectives. Time will be reserved for debate between panellists, focusing about points of divergence in opinion, with participation of the audience.
Samuel Aballea, PhD
Creativ-Ceutical, Paris, 75, France
Omar Dabbous, MD, MPH
AveXis, Inc., Bannockburn, USA
Ataru Igarashi, PhD
Tokyo University, Tokyo, Japan
Mondher Toumi, MD, MSc, PhD
Aix-Marseille University, Marseille, France
PURPOSE
DESCRIPTION
Mingqiang Li, PhD.
Taikang Insurance Group, Beijing, China
Wahseng Lim, PhD. MBA
Takeda China, Beijing, China
Gordon Liu, PhD.
National School of Development, Peking University, Beijing, China
Monica Martin De Bustamante, AB, BE
CBPartners, New York City, NY, USA
Zeba M. Khan, RPh, PhD and Laura T. Pizzi, PharmD, MPH will review the hot topics of the day, conduct interviews with key presenters, and preview upcoming events for the next day.
Add the “News Desk” to your daily conference agenda and tune in to see how health economics and outcomes research is informing healthcare decisions around the world.
Elina Hypponen, PhD, MPH, MSc
Australian Centre for Precision Health, University of South Australia Cancer Research Institute, Adelaide, Australia
Yeul Hong Kim, MD, PhD
Korea University College of Medicine, K-MASTER Cancer Precision Medicine Diagnosis and Treatment Enterprise, Seoul, Korea, Republic of (South)
Kazuhiko Yamamoto, MD, PhD
RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
Teo Yik Ying, PhD
National University of Singapore, Singapore, Singapore
Xiaotian Zhang, MD, PhD
Peking University Cancer Hospital & School of Oncology, Beijing, China
Day 2 Topic: HEOR within the Next-Generation Healthcare Paradigm: Perspectives within the ISPOR Community
Panelists Shanlian Hu, MD, MSc, Fudan University, Shanghai, China , Vivian WY Lee, BSc, PharmD, Chinese University of Hong Kong; Trudy Sullivan, PhD, University of Otago, New Zealand; Jitendar Sharma, PhD, Andrha Pradesh Medtech Zone, India; Richard J. Willke, PhD, ISPOR; Lucinda Orsini, DPM, MPH, ISPOR
This 30-minute session brings together an esteemed panel of thought leaders in the region to talk about how the wave of technological innovation is transforming healthcare for all stakeholders. What are the greatest challenges that new modes of healthcare such as precision medicine and digital health posing to health systems? What are the key opportunities? And how can HEOR help fill the gap? These are just some of the questions we will be debating. Join us for this interactive session.
PURPOSE: Balancing improvement in population health while maintaining a sustainable healthcare budget is increasingly challenging worldwide. Biosimilars which have already been introduced in several regions and will become available in Asia Pacific can contribute to addressing unmet medical needs while supporting healthcare budget management. This workshop will present an overview of global access and adoption landscape for biosimilars, analyze barriers, and discuss solutions from distinct perspectives covering clinical, economic and humanistic aspects.
DESCRIPTION: Payers in Asia-Pacific are under scrutiny to control healthcare expenditure and to enhance the sustainability of healthcare systems. Pressure on healthcare budget will likely continue to increase due to numerous factors including aging populations and innovative therapies. Moreover, some countries in the region are experiencing limited access to medicines, especially biologic drugs, due to budget constraints. Biosimilars have the potential to expand access1 to life-saving therapies and to reduce healthcare costs. Despite this seemingly positive outlook, adoption of biosimilars in the region remain suboptimal notwithstanding the recent market entry of a growing number of biosimilars. Recent improvement in biosimilar uptake in Europe and the US can serve as a benchmark for stakeholders in Asia Pacific and demonstrate how various healthcare systems have successfully managed biosimilar uptake.
Leah Christl, PhD
Amgen Inc., Washington, DC, USA
Colin Ge, PhD
IQVIA, San Francisco, CA, USA
Ka On Lam, MBBS, FRCR, FHKCR, FHKAM
The University of Hong Kong, Hong Kong, Hong Kong
Arnold Vulto, PhD, PharmD, FCP
The Erasmus University Medical Center, Rotterdam, Netherlands
Devarshi Bhattacharyya, BDS, MSc, MPH
Eli Lilly and Company, Bengaluru, India
Yingyao Chen, PhD
Fudan University, Shanghai, China
Naoko Ronquest, PhD
RTI Heatlh Solutions, Durham, NC, USA
Schezn LIM, BSc (Pharm) MSc PGCert (Health Economics)
Costello Medical Singapore Pte Ltd, SINGAPORE, Singapore
Sukyeong Kim, PhD, RPh, MPH
National Evidence-based Health Care Collaborating Agency (NECA), Seoul, South Korea
Hang Le, PhD
Roche Pharma International, Singapore , Singapore
IQVIA
Yang Xie, PhD.
IQVIA, Shanghai, China
Lou Garrison, PhD
University of Washington, Seattle, WA, USA
George Papadopoulos, BSc(Hons), GradDipEpi
Lucid Health Consulting Pty. Ltd., NSW, Australia
Raoh-Fang Jasmine Pwu, PhD
Ministry of Health and Welfare, Taipei, Taiwan
Vanessa Schaub, PhD
F.Hoffmann-La Roche, Switzerland
PURPOSE: The Korean Government announced in December 2006 that only medications offering good value for money, will be reimbursed in the Korean National Health Insurance (NHI) programme (the Positive List System, or PLS). With the introduction of the PLS, the Health Insurance Review and Assessment Service (HIRA) published the first version of the Korean pharmacoeconomic evaluation guidelines in 2006. The 2nd version was announced in 2011 and the 3rd version is scheduled to be announced in 2020. The purpose of this workshop is to share the overview of the 3rd version of the Korean economic evaluation guidelines.
DESCRIPTION: Professor Lee will lead the discussion as a moderator, and Professor EY Bae will provide overview of the direction of the revision. Professor An will overview the major statistical considerations in the revision. Professor Hong will review the health-related quality of life (HRQoL) data submitted to HIRA and discuss HRQoL-related issues raised in the revision.
Hyonggin An, Ph.D.
Korea University, college of medicine, Seoul, South Korea
Eun Young Bae, PHD
Gyong-Sang National University, South Korea, Jinju, Gyeongnam province, South Korea
Seungjin Bae, SC.D.
Ewha Womans University, College of Pharmacy, Seoul, Korea, Republic of (South)
Jihyung Hong, PhD
Gachon University, Seongnam, South Korea
Tae Jin Lee, PhD
Seoul National University, Seoul, South Korea
PURPOSE: Although several EQ-5D-5L valuation studies have been conducted in the Asian region, including China, Hong Kong, Indonesia, Japan, Malaysia, Singapore, South Korea, Taiwan, Thailand, and Vietnam, published value sets differ across health jurisdictions. Accounting for these variations is complicated by several factors that include underlying differences in healthcare governance, finance and organization. Variability attributable to the valuation methods used is imperfectly understood. The use of EQ-VT (a standardized method for eliciting health state valuations) has helped to improve data quality; differences in data analysis strategies and the details of modelling methods may nevertheless still contribute to variations between value sets.
DESCRIPTION: The workshop will begin with an introduction to the current state of play in EQ-5D-5L valuation in the Asian region. Key elements of the EQ-VT procedure will be described, for example the use of the lead-time form of TTO to value states worse than dead. The robustness of data across valuation studies will demonstrated using pre-defined criteria. Internal consistency between DCE and TTO methods will be compared. A panel-led discussion will explore potential explanations for the observed differences in regional EQ-5D-5L value sets. The implications of this variation in values for health policy will be exemplified. Recommendations for the future conduct of valuation studies will be proposed
Ling-Hsiang Chuang, PhD
GongJing Healthcare, IJsselstein, Netherlands
Paul Kind, PhD
University of Leeds, Leeds, United Kingdom
Nan Luo, PhD
Oshima Sachin, PhD
Department of Health Research, New Delhi, DL, India
Budi Hidayat, SKM, MPPM, PhD
University of Indonesia, Depok, Indonesia
Andrew Wilson
Pharmaceutical Benefits Advisory Committee (PBAC), Canberra, Australia
Kun Zhao, MD, MHSci, PhD
China National Health Development Research Center, Beijing, China
Diane Munch, MA
Pfizer, Inc., New York, NY, USA
Sarah Fitt, BPharm
Pharmaceutical Management Agency (PHARMAC), Wellington, New Zealand
Shanlian Hu, MSc, MD
School of Public Health, Fudan University, Shanghai, China
Netnapis Suchonwanich
Health Intervention and Technology Assessment Program (HITAP), Bangkok, Thailand
Day 3 Topic: New Pathways for Patient Access – Engaging with all Healthcare Stakeholders – A Group Discussion
Panelists: Ratna Devi, MBA, MBBS, DakshamA Health, India; Bruce Crawford, MA, MPH, Syneos Health, Japan; Hong Li, PhD, MPH, Amgen, Hong Kong; Viva Ma, PhD, MPH, MBA, Becton Dickinson, Singapore; Richard J. Willke, PhD, ISPOR; Lucinda Orsini, DPM, MPH, ISPOR
This 30-minute session brings together an esteemed panel of thought leaders in the region to talk about stakeholder roles in exploring different approaches to overcoming access barriers. Where can the role of the patient voice be strengthened in patient access efforts? What are the future directions for broader stakeholder dialogue and engagement in healthcare? These are just some of the questions we will be debating. Join us for this interactive session.
PURPOSE:
DESCRIPTION:
Turgay Ayer, PhD.
Georgia Institute of Technology, Atlanta, GA, USA
Jag Chhatwal, PhD
Georgia Institute of Technology, Boston, USA
Selin Merdan, Ph.D.
Value Analytics Labs, Kennesaw, GA, USA
Joe Caputo, BSc (Hons)
MYDOC PTE LTD, Singapore, Singapore
Korea University Guro Hospital, Seoul, South Korea
Isao Kamae, MD, DrPH
The University of Tokyo, Tokyo, 13, Japan
Marius van den Berg, DBA
Illumina Singapore Pte Ltd, Singapore, Singapore
Ann Single, BBus MA
Patient Voice Initiative, Ashgrove, QLD, Australia
Philip Hope, Dip. Bus. Hons. CFRM MFINZ
Lung Foundation New Zealand, Auckland, New Zealand
Jinyoung Paik, NA
Korea Kidney Cancer Association, seoul, South Korea
Jane Tsai, NA
Formosa Cancer Foundation Taiwan, Taipei, TPQ, Taiwan
MED-CON--00001-GLO
AveXis, Inc.
Michael Drummond, MCom, DPhil
Bocconi University, York, YOR, United Kingdom
Sean Sullivan, PhD, MSc, RPh
ISSUE:
OVERVIEW:
Dong-Chul Suh, PhD
ChungAng University, Seoul, Korea, Republic of (South)
Brian Godman, PhD
Karolinska Institutet, Stockholm, Sweden
Kevin Haninger, PhD
Pharmaceutical Research and Manufacturers of America (PhRMA), Washington DC, DC, USA
Eun-Sook KIM, PhD
UCB Korea, Seoul, Korea, Republic of (South)
Soomi So, PhD
Health Insurance Review and Assessment Service (HIRA), Seoul, South Korea
ISSUE: Despite the increasing number of RWD/RWE studies being conducted and the growing potential of converting RWD to RWE, RWE has not been used extensively to inform decision-making in developed HTA systems. Given the rapid development of HTA systems and the accelerating evolution of RWE in Asia, examination is required of whether developing HTA systems can forge ahead with RWE use.
OVERVIEW: This panel will describe the current use of RWD/RWE in HTA processes and the learnings from established HTA systems, evaluate the current availability, accessibility, and quality of RWD/RWE in Asia, and determine if and how developing HTA systems in Asia can lead the way with RWD/RWE use.
Qian Ma, Double Bachelor Degrees
Costello Medical, Singapore, Singapore
Hao Hu
Gilead Sciences, Hong Kong, Hong Kong
Pilar Pinilla, MSc
National Institute for Health and Care Excellence, London, United Kingdom
Hwee-Lin Wee, PhD
Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
Adrian Towse, MA, MPhil
Office of Health Economics, London, United Kingdom
Richard Vines, TBA
Rare Cancers Australia, Bowral NSW, Australia